proinnovera has successfully closed recruitment of a global Phase 2b study in mild to moderate Atopic Dermatitis 10 weeks ahead of schedule.

Recruitment closed ahead of schedule

proinnovera has successfully closed recruitment of a global Phase 2b study in mild to moderate Atopic Dermatitis 10 weeks ahead of schedule.